Fig. 1From: Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective studyComparison of eGFR at baseline, after 1 month of antiviral therapy, and after 3 months of antiviral therapy Box plot of eGFR at baseline, after 1 month of antiviral therapy, and after 3 months of antiviral therapy. (A) Molnupiravir, (B) RemdesivirBack to article page